Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Manufacturing and Selling of Medicines and Medical Devices	551.50M	576.48M	611.48M	724.77M	547.80M
Sales and Distribution of Medicines and Healthcare Products and Medical Devices	490.00M	523.05M	554.63M	326.96M	337.32M
Elimination of Inter-Segment	-69.49M	-57.83M	-101.25M	-65.05M	-46.31M
Total	972.01M	1.04B	1.06B	986.69M	838.81M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
People's Republic of China (PRC)	972.01M	1.04B	1.06B	986.69M	838.81M
Total	972.01M	1.04B	1.06B	986.69M	838.81M

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 27, 2026

Data Sources Report a data error